TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16893434
Drug: placebo-simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo-simvastatin 20 mg
Study: 15336577
Drug: Intravenous regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous regular insulin
Study: 10950401
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (amlodipine 5 mg and doxazosin 2 mg)
Study: 10950401
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with doxazosin 4 mg
Study: 10950401
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with amlodipine 10 mg
Study: 9305715
Drug: Carboplatin plus
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin plus amifostine (500 mg/m2 carboplatin + 2 doses of 910 mg/m2 amifostine)
Study: 9305715
Drug: Carboplatin alone
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin alone (500 mg/m2)
Study: 8422661
Drug: Selegiline 0
Normalized name: selegiline 0.5 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline 0 mg daily (placebo)
Study: 3537783
Drug: Intravenous edrophonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous edrophonium (Tensilon)
Study: 29582447
Drug: Sleep study-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep study-guided multidisciplinary therapy (SGMT) including overnight sleep study, continuous positive airway pressure, and behavioral therapy for OSA.
Study: 29582447
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for acute coronary syndrome (ACS).
Study: 22388001
Drug: Nebivolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (10 mg and 20 mg daily)
Study: 20478471
Drug: Triple antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple antibiotic mixture (ciprofloxacin, metronidazole, minocycline)
Study: 20478471
Drug: Minocycline (component
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (component of the triple antibiotic paste)
Study: 18387728
Drug: Dentin bonding
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentin bonding agent
Study: 15939717
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy with 5-Fluorouracil (5-FU) and cisplatin
Study: 7751410
Drug: Linopirdine (DuP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linopirdine (DuP 996) 0.5 to 55 mg in young subjects; 20 to 45 mg in elderly subjects
Study: 2148280
Drug: Low-dose enoximone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose enoximone
Study: 2148280
Drug: High-dose enoximone
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose enoximone
Study: 359109
Drug: Butorphanol 1
Normalized name: butorphanol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 1 mg and 2 mg
Study: 359109
Drug: Meperidine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 40 mg and 80 mg
Study: 31222759
Drug: Metabolite-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolite-guided treatment approach
Study: 26069973
Drug: Wet cupping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wet cupping therapy (6 sessions within 2 weeks at two bladder meridian acupuncture points)
Study: 23791771
Drug: Professionally applied
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professionally applied dentine bonding agent (DA)
Study: 21680999
Drug: Remoxy 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxy 5 mg twice daily (10 mg total daily oxycodone dose) for opioid-naïve patients; equivalent dose for opioid-experienced patients based on previous opioid daily dose.
Study: 14713399
Drug: Cyclooxygenase-2 selective
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclooxygenase-2 selective agents
Study: 7516450
Drug: CODE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CODE plus G‐CSF (cyclophosphamide, Oncovin, doxorubicin, etoposide with granulocyte-colony stimulating factor)
Study: 2887173
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg WAL 801 CL
Study: 2887173
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg WAL 801 CL
Study: 2887173
Drug: 18 mg
Normalized name: niacin 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg WAL 801 CL
Study: 2887173
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg ketotifen
Study: 27635789
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose CT (120 kVp, 100 mAs)
Study: 24628076
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl 25 mcg
Study: 24431884
Drug: Insulin syringe
Normalized name: Insulin Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin syringe
Study: 21353107
Drug: Colchicine 0.6
Normalized name: colchicine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.6 mg/d or Naproxen 250 mg BID for 8 weeks
Study: 21353107
Drug: Colchicine 0.6
Normalized name: colchicine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.6 mg/d or Naproxen 250 mg BID for 6 months
Study: 21353107
Drug: Mean postbaseline
Normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean postbaseline sUA concentration <6.0 mg/dL
Study: 18275573
Drug: Progesterone suppository
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone suppository (400 mg) daily until delivery
Study: 14969070
Drug: Early DMARD
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early DMARD group (hydroxychloroquine, intramuscular gold, oral methotrexate)
Study: 14969070
Drug: iAU therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: iAU therapy
Study: 10382188
Drug: Liquid nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid nutritional supplement between meals and at bedtime
Study: 8694698
Drug: pyruvate-based peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyruvate-based peritoneal dialysis solution (pH 5.2)
Study: 8694698
Drug: lactate-based peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactate-based peritoneal dialysis solution (control)
Study: 6341639
Drug: Rhesus diploid‐cell‐strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus diploid‐cell‐strain rabies vaccine (RDRV)
Study: 6341639
Drug: Rhesus diploid‐cell‐strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus diploid‐cell‐strain rabies vaccine (RDRV) without prior rabies immune globulin
Study: 27128218
Drug: AZD6280 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6280 10 mg
Study: 27128218
Drug: AZD6280 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6280 40 mg
Study: 21309709
Drug: Derris scandens
Normalized name: Senecio scandens flowering top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Derris scandens Benth extracts 800 mg/day
Study: 11597664
Drug: Bosentan (62.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (62.5mg taken twice daily for 4 weeks then 125 mg twice daily)
Study: 9408514
Drug: Gentamicin 7
Normalized name: gentamicin 70 mg/50 mL-0.9% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 7 mg/kg i.v. once daily by itself
Study: 9408514
Drug: Gentamicin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin with piperacillin 4 g and tazobactam 0.5 g every six hours i.v.
Study: 9408514
Drug: Gentamicin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin with piperacillin 4 g and tazobactam 0.5 g every eight hours i.v.
Study: 9408514
Drug: Gentamicin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin with piperacillin 8 g and tazobactam 1 g by continuous i.v. infusion over 24 hours
Study: 7961338
Drug: Fluoxetine at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine at a dose of 0.6 mg/kg/day
Study: 3328992
Drug: Anxiety Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anxiety Management (self-help treatment including procedures for managing somatic and cognitive symptoms, avoidance, and low self-confidence)
Study: 28057390
Drug: Lornoxicam 16mg
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 16mg administered 60 minutes before surgery
Study: 28057390
Drug: Lornoxicam 16mg
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 16mg administered 60 minutes after surgery
Study: 28057390
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 60 minutes before surgery
Study: 28057390
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 60 minutes after surgery
Study: 23143621
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg thalidomide once/day
Study: 23143621
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g sulfasalazine, twice/day
Study: 23143621
Drug: NSAIDs for
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAIDs for maintenance treatment
Study: 21722168
Drug: Heparin (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (0.7 mL, 10 units/mL)
Study: 21722168
Drug: Saline (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.7 mL)
Study: 16540702
Drug: Other SGA
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other SGA drugs
Study: 10736383
Drug: Monosodium glutamate
Normalized name: Monosodium Glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosodium glutamate (MSG) at a dose of 2500 mg
Study: 9363292
Drug: Valproate (individualized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate (individualized dosing according to response and side effects)
Study: 1313100
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg minocycline per day for 8 days
Study: 1313100
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg minocycline per day for 8 days
Study: 4008643
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha (IFN) at a dose of 3 X 10(6) U
Study: 4008643
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha (IFN) at doses of 3 X 10(6), 10(7), and 3 X 10(7) U
Study: 4008643
Drug: Pre-injection PMC
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-injection PMC cultured overnight
Study: 26525369
Drug: OFIRMEV 1
Normalized name: Ofirmev 10 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: OFIRMEV 1 g every 6 hours for 24 hours
Study: 22130164
Drug: Ipilimumab at
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab at 10 mg/kg every 3 weeks for 4 doses
Study: 22130164
Drug: Budesonide (oral)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (oral)